Immuneering (IMRX) Change in Acquisitions & Divestments (2022 - 2026)

Immuneering's Change in Acquisitions & Divestments history runs 4 years deep, the most recent figure standing at $9.0 million for Q1 2026.

• On a quarterly basis, Change in Acquisitions & Divestments changed N/A year-over-year to $9.0 million in Q1 2026; TTM through Mar 2026 was $9.0 million, a 14.29% decrease from a year earlier, with the FY2024 full-year figure at $31.9 million, down 38.95% from the prior year.
• Change in Acquisitions & Divestments improved to $9.0 million in Q1 2026 per IMRX's latest filing, from $5.5 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $32.3 million in Q2 2022 and bottomed at $5.0 million in Q3 2023.
• The 4-year median for Change in Acquisitions & Divestments is $19.0 million (2023), against an average of $15.5 million.
• Across the five-year window, Change in Acquisitions & Divestments sank 74.03% in 2023 and grew 12.79% in 2024, its largest moves.
• Year by year, Change in Acquisitions & Divestments stood at $20.6 million in 2022, then decreased by 7.52% to $19.0 million in 2023, then tumbled by 71.13% to $5.5 million in 2024, then surged by 63.64% to $9.0 million in 2026.
• Per Business Quant, the three latest IMRX Change in Acquisitions & Divestments figures stand at $9.0 million (Q1 2026), $5.5 million (Q4 2024), and $5.0 million (Q2 2024).